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iabetic retinopathy is the leading cause of blind-
ness in the Western world (1) and is character-
ized by abnormal angiogenesis driven by
several factors, including tissue ischemia and
hyperglycemia. This abnormal angiogenesis results in new
vessels that are often immature and play a pathological
role in retinopathy, contributing to both vitreous hemor-
rhage and ﬁbrosis (2). In addition, increased vascular
permeability leading to plasma leakage accounts for the
development of macula edema, disrupting visual function
(2). These evidences have led to the development of
several therapeutic strategies targeting angiogenesis in
diabetic retinopathy (3).
Abnormal angiogenesis also occurs in diabetic nephrop-
athy; therefore, the overriding question is whether new
vessel formation in the kidney plays a pathological role in
diabetic nephropathy similar to that observed in retinop-
athy. Intriguingly, the progression of both diabetic retinop-
athy and nephropathy is altered by vascular growth factor
signaling through receptor tyrosine kinases, speciﬁcally
involving the vascular endothelial growth factor (VEGF)-A
and angiopoietin families. This review discusses abnormal
angiogenesis and the role of both VEGF-A and angiopoi-
etins in diabetic nephropathy.
Evidence of abnormal angiogenesis in diabetic ne-
phropathy. In 1987, Osterby and Nyberg (4) described
abnormal blood vessels in glomeruli of patients with
long-term type 1 diabetes, and later these ﬁndings were
shown to occur in type 2 diabetic patients (5,6) (Fig. 1A).
The abnormal vessels occupied 1–5% of glomerular capil-
lary area, they were occasionally dilated, and the glomer-
ular basement membrane adjacent to them was found to
be focally extremely thin. Abnormal vessels were also
present in Bowman’s capsule or in the glomerular vascular
pole, the latter of which could often be detected as an
“extra efferent arteriole” (4,7). Min and Yamanaka (8) then
performed detailed analyses of computer-generated three-
dimensional images in 94 patients with diabetic nephrop-
athy and found the presence of extravessels. Intriguingly,
in this study the abnormal vessels anastomosed to the
lobular structure of the intraglomerular capillary network,
mainly to afferent branches through the widened vascular
hilus, while the distal end of the vessels connected to the
peritubular capillary. In these vessels, native endothelial
cell function was likely impaired, with the endothelial cells
initially swollen and endothelial thickness gradually de-
creasing as diabetes progressed (9,10). It was also docu-
mented that the vascular wall was thickened, owing to an
accumulation of matrix in these arterioles (10). Of impor-
tance was the ﬁnding that these vessels were observed in
diabetic patients during the ﬁrst 2 years of disease (8),
which supports the contention that the development of
these vessels occurs even in the early phases of diabetic
nephropathy.
In diabetic animals, Nyengaard and Rasch (11) identiﬁed
abnormal glomerular capillaries in an animal rat model
induced by streptozotocin. They determined that after
both 10 and 50 days following injection, the average total
surface area, length, and numbers of glomerular capillaries
were elevated compared with those of controls. Similarly,
db/db mice were found to exhibit increased endothelial
cell number and elongation of capillaries in their glomeruli
(12,13). Recently, the occurrence of excessive blood ves-
sel formation in diabetes has been demonstrated by im-
munohistochemistry using endothelial cell markers. As
shown in Fig. 1B, endothelial cell staining was increased in
streptozotocin-induced diabetic animals (13–16). How-
ever, it should be noted that the later stages of diabetic
nephropathy are accompanied by capillary loss and rar-
efaction in both humans and animal models, a concept
that is discussed below (5,15,17).
The pathological role of abnormal angiogenesis in
diabetic nephropathy. While the pathological role of
abnormal vessels remains unclear, it has been demon-
strated that neovascularization is associated with glomer-
ular hypertrophy in diabetic nephropathy. Morphological
changes in capillaries such as elongation and increased
number contribute to glomerular hypertrophy in both
humans and animals with diabetes, whereas changes in
mean capillary diameter do not correlate with alterations
in glomerular volume (7,12). Interestingly, the develop-
ment of abnormal vessels was observed in the extraglo-
merular area and associated with glomerular hypertrophy
in both diabetic animals and patients (6,10). Osterby et al.
(7) performed a series of studies using electron micros-
copy and found that abnormal vessels in the vascular pole
were associated with enhanced glomerular hypertrophy
and increased frequency of glomerular capillary occlusion,
ﬁbrinoid lesions, tubulointerstitial injury, and urinary al-
bumin excretion (6,10,18). Additionally, recent evidence
has indicated that blocking angiogenesis attenuated glo-
merular basement membrane thickening, mesangial ex-
pansion, and transforming growth factor (TGF)-1
expression in diabetic animals (13,14,16), suggesting that
these vessels have a causal role in the development of
early features of diabetic nephropathy.
The abnormal additional vessels found in diabetes pos-
From the
1Division of Renal Diseases and Hypertension, University of
Colorado Denver, Aurora, Colorado; the
2Second Department of Internal
Medicine, Asahikawa Medical College, Asahikawa, Japan; and the
3Nephro-
Urology Unit, UCL Institute of Child Health, London, UK.
Corresponding author: Takahiko Nakagawa, takahiko.nakagawa@ucdenver
.edu.
Received 28 January 2009 and accepted 26 March 2009.
DOI: 10.2337/db09-0119
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
DIABETES, VOL. 58, JULY 2009 1471sess a thin wall at the basement membrane, while endo-
thelial cells are swollen, suggesting that they are
structurally immature and capable of causing an increase
in vascular permeability (4,9,19). An increase in capillary
permeability often results in the extravasation of plasma
protein as well as the forming of lesions in diabetic
nephropathy. For example, the capsular drop, ﬁbrin cap,
and arteriolar hyalinosis, all of which characterize human
diabetic nephropathy, can be considered a consequence of
plasma leakage (20). Furthermore, recent studies docu-
mented that leakage of plasma protein results in the
development of atubular glomeruli in type 1 diabetic
patients (21). A potential mechanism for this observation
could be due to the glomerular and peritubular ﬁltrate
spreading into the glomerulo-tubular junction to eventu-
ally separate proximal tubules from the glomerulus (22).
Given these facts, the extravasations from immature ves-
sels could have a causal role in the development of
diabetic nephropathy.
Mechanisms for the development of abnormal angio-
genesis in the diabetic kidney. Angiogenesis is often
associated with an increase in endothelial number caused
by an imbalance in cell proliferation and apoptosis. Re-
cently, Hohenstein et al. demonstrated that in type 2
diabetic patients, an increased endothelial number was
observed and early glomerular lesions were caused by a
combination of increased proliferation and decreased ap-
optosis in glomerular endothelial cells (5). A major driver
in this process appears to be VEGF-A expression, which is
induced by high glucose levels in the early phases of
diabetes and can stimulate endothelial cell proliferation
and inhibit apoptosis. In addition, high glucose levels
alone can enhance endothelial cell proliferation (23).
Therefore, the beneﬁcial effect of insulin treatment to
block the progression of extravessels in patients with type
1 diabetes (7) could be attributed to reduced blood glu-
cose levels and inhibition of VEGF-A expression (15).
Glomerular hypertension may be another important
driver in the progression of abnormal angiogenesis in
diabetes. Osterby et al. (7) demonstrated that treatment
with ACE inhibitors or -blockers for 8 years to reduce
hypertension in diabetic patients suppressed progression
of glomerular lesions and extravessel formation. In a
similar fashion, we found that lowering blood pressure in
a novel animal model of diabetic nephropathy using endo-
thelial nitric oxide synthase (eNOS) knockout (eNOSKO)
mice and steptozotocin injection led to attenuated pro-
gression of abnormal angiogenesis. These mice developed
abnormal vessels accompanied by advanced lesions in-
cluding nodular lesions and mesangiolysis (15). As shown
in Fig. 1C, lowering blood pressure in these animals using
hydralazine blocked the development of abnormal angio-
genesis and inhibited glomerular VEGF-A expression (24).
These data suggest that the beneﬁcial effect of lowering
blood pressure could be mediated by VEGF-A inhibition.
Alternatively, one could postulate that these vessels func-
tion as a by-pass to reduce intraglomerular pressure given
that abnormal vessels were found to connect intraglo-
merular capillaries to peritubular capillaries (8). Hence,
reducing intraglomerular pressure as a consequence of
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FIG. 1. Abnormal angiogenesis in diabetic nephropathy. A: Extraglomerular neovascularization (black arrows) are found in type 2 diabetic
patients. Reprinted with permission from ref. 6. B: Similarly, immunohistochemistry for CD34, a marker for endothelial cells, indicates the normal
glomerular capillary pattern (brown) in nondiabetic C57BL6 mice (a). Alternatively, abnormal capillary formation is observed around glomerulus
in diabetic mice lacking endothelial nitric oxide synthase (b), resembling abnormal angiogenesis in human diabetic nephropathy. Reprinted with
permission from ref. 33. C: The association of abnormal angiogenesis with VEGF expression in diabetic eNOSKO mice. In contrast to glomerulus
in normal mice, glomerular endothelial staining is increased along with VEGF expression. However, hydralazine treatment attenuates the
increase in glomerular capillary number and VEGF expression in diabetic eNOSKO mice. D: Glomerular ﬁltrate and atubular glomerulus in
diabetic eNOSKO mice. Glomerular ﬁltrates are delivered to the outside of the glomerulus (arrow in a) and spread to the glomerulotubular
junction (arrows in a and b). This ﬁltrate may lead to a disconnection between glomerulus and proximal tubules (b). Ballooning of Bowman’s
capsule is observed in c. Glomeurlar ﬁltrate can be observed outside of Bowman’s capsule in the tubular pole, where the proximal tubulus is
completely disconnected from the glomerulus. Bar  40 m. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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for the development of by-pass vessels. A depiction of the
factors affecting abnormal angiogenesis and their patho-
logical effects is shown in Fig. 2.
VEGF as a mediator of abnormal angiogenesis in
diabetic nephropathy. The VEGF-A family has a role in
the development, maintenance, and remodeling of the
vasculature, acting through the receptor tyrosine kinases
VEGFR-1 and VEGFR-2 (25). The VEGF-A family is very
complex with several isoforms generated by alternative
splicing of exons 6 and 7. In diabetes, the VEGF-A164 and
VEGF-A188 isoforms are increased and can be reduced by
insulin treatment (26). Additional isoforms with anti-an-
giogenic properties termed VEGF-Axxxb occur due to exon
8 distal splice site selection (25), leading to an unique
carboxy-terminal sequence.
Several studies have examined the expression pattern of
the VEGF-A family in diabetic animals and patients. Coo-
per et al. (27) examined VEGF-A and VEGFR-2 in short-
and long-term diabetic rats (3 and 32 weeks following
streptozotocin injection, respectively). Short-term diabe-
tes led to elevated VEGF-A and VEGFR-2 mRNA, whereas
in long-term diabetic animals VEGF-A remained elevated
and VEGFR-2 was unaltered. VEGF-A was localized to
podocytes and, to a lesser extent, tubular epithelial cells,
whereas VEGFR-2 was expressed in glomerular and peri-
tubular capillaries. Elevated VEGF-A has been conﬁrmed
in our animal model of diabetic nephropathy using
eNOSKO mice (15). The mice developed excessive vessels
in glomeruli and tubulointerstitium that were associated
with upregulation of glomerular VEGF-A expression. Ele-
vation of VEGF-A has also been observed in human biopsy
samples where the number of extravessels around the
glomerular vascular pole was associated with upregulation
of VEGF-A expression in the kidney (6). Finally, examina-
tion of urinary VEGF-A showed signiﬁcant elevations in
type 2 diabetic patients (28), compared with healthy
control subjects, that positively correlated with urinary
albumin-to-creatinine ratio and negatively correlated with
creatinine clearance.
A potential consequence of high levels of VEGF-A will
be enhanced vascular permeability in the glomerulus (29).
In addition, low NO (nitric oxide) bioavailability observed
in diabetes (30,31) could be an additional contributor to
the increased vascular permeability. Predescu et al. (32)
documented that low levels of endothelial-derived NO
altered the integrity of interendothelial junctions in capil-
laries, resulting in an increase in vascular permeability. As
such, a low NO bioavailability along with high VEGF-A
expression (we term this condition “uncoupling of
VEGF-A with NO”) observed in the diabetic milieu of
eNOSKO mice could potentiate the vascular permeability
in the glomerulus and cause glomerular injury in diabetic
nephropathy (15,33). Intriguingly, this uncoupling condi-
tion could also cause the development of abnormal angio-
genesis. This notion can be supported by recent evidences
from our laboratory and other groups that NO can nega-
tively regulate VEGF-A–induced endothelial proliferation
(34), whereas NO deﬁciency enhances VEGF-A activity,
leading to endothelial proliferation (35). We have exten-
sively reviewed a causal role of this uncoupling condition
in other types of vascular diseases, including coronary
artery disease, remnant kidney, and angiotensin II–in-
duced renal injury in previous work (33). It should be
noted that while the aforementioned studies indicate low
NO contributing to capillary hyperpermeability, Tilton et
al. (36) demonstrated that supra-physiological NO posi-
tively mediates hyperpermeability in response to exoge-
nous VEGF-A in several different nondiabetic tissues.
Therefore, it is likely that physiological levels of NO are
required to maintain low vascular permeability and that
NO levels that are either too high or too low (depending on
the biological situation) may lead to hyperpermeability.
VEGF-A is lowered in the advanced stage of diabetic
nephropathy. The study by Cooper et al. (27) suggested
that although VEGF-A may be elevated in the initial phases
of diabetic nephropathy, it may not be maintained as more
chronic ﬁbrotic changes occur in the kidney. Indeed, in
many animal models of chronic kidney disease, VEGF-A
levels are reduced, correlating with the progression of
renal damage (37,38). To examine this in diabetic nephrop-
athy, Baelde et al. (17) used laser-capture microdissection
to determine gene expression in glomeruli from 28 dia-
betic patients. They observed a reduction of 2.5-fold in
VEGF-A expression in severely injured glomeruli as evi-
denced by a loss of endothelial cells and a reduction in
podocyte markers (WT-1, nephrin, and podocin mRNAs)
(17). Given that podocytes and tubular epithelial cells are
the primary source of VEGF-A in the kidney, the mecha-
nism for a reduction in VEGF-A expression in severe renal
injury could be attributed to the inability of these cells to
produce VEGF-A due to advanced stages of cellular injury.
Other studies have found that VEGF-A expression was
decreased in sclerotic areas and in nodular lesions of
diabetic nephropathy (39,40). In addition, Zucker diabetic
fatty rats exhibited a decline in renal VEGF-A expression
in advanced stages of diabetic nephropathy (41,42). This
interesting concept was highlighted in an elegant study by
Hohenstein et al. (5) where they used speciﬁc antibodies
to examine not only VEGF-A expression but also receptor-
bound VEGF-A as a marker of bioactivity in diabetic
patients. In their study, although VEGF-A expression was
increased in all diabetic glomeruli by many cell types,
VEGF-A activity was only increased in the endothelium of
mildly injured glomeruli and signiﬁcantly decreased in
more severe glomeruli (5). This data suggests that the
upregulation of VEGF-A in early stages of diabetic ne-
phropathy may provide a mechanism for the initial pro-
gression of the disease, leading to excessive blood vessel
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FIG. 2. Mechanism and pathogenic role of abnormal angiogenesis in
diabetic nephropathy.
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diabetic nephropathy may reﬂect a loss of endogenous
VEGF-A due to the disruption of podocytes and tubular
cells in chronic kidney damage (Table 1).
Alterations in angiopoietin balance as a molecular
mechanism of diabetic nephropathy. A second family
of growth factors implicated in the progression of diabetic
nephropathy are the angiopoietins, which are critical for
the normal vascular differentiation, maintenance, and
turnover of blood vessels in mature animals (43). Angio-
poietin-1 and -2 are ligands for the Tie-2 receptor tyrosine
kinase, expressed mainly by endothelia; angiopoietin-1
stimulates receptor activation, leading to promotion of
endothelial survival and stabilization. Angiopoietin-2 is
considered a natural antagonist of angiopoietin-1 (44),
although other data suggest that high concentrations of
angiopoietin-2 may activate Tie-2 (45). Alterations in the
expression of the angiopoietins have been implicated in
the progression of diabetic nephropathy (rev. in 43). In
addition, transgenic mice with inducible overexpression of
angiopoietin-2 in podocytes in otherwise normal healthy
adult animals develop signiﬁcant increases in albuminuria
(46), a parameter that correlates with, and can predict, the
progression of renal damage in diabetes (47). Collectively,
these observations suggest that a decreased ratio of an-
giopoietin-1 to angiopoietin-2 might play a role alongside
VEGF-A in the pathobiology of diabetic nephrology. Im-
portantly, the biological effects of angiopoietin-2 are con-
text dependent and, in vivo, depend on ambient levels of
VEGF-A, such that vessel regression occurs if VEGF-A is
lacking, whereas vessel destabilization followed by angio-
genesis occurs if the local milieu is rich in VEGF-A (44). It
could be postulated that the increased levels of angiopoi-
etin-2 alongside a VEGF-A–rich milieu in glomeruli during
the initial phases of diabetes will lead to the destabiliza-
tion of blood vessels and hence excessive angiogenesis.
Therefore, it is possible that modulation of the balance
between angiopoietin-1 and -2 may have therapeutic po-
tential in diabetic nephropathy.
Targeting angiogenesis to treat diabetic nephropa-
thy. Given the evidence above, there is a rationale for
targeting angiogenic pathways to prevent diabetic ne-
phropathy, and several studies have now blocked VEGF-A
activity as a therapy to prevent abnormal angiogenesis. An
elegant genetic approach was recently taken by Gnudi and
colleagues (48) by blocking VEGF-A signaling in mice
administered streptozotocin through overexpressing solu-
ble VEGFR-1, speciﬁcally in podocytes. Diabetic mice that
overexpressed soluble VEGFR-1 had attenuated albumin
excretion, mesangial expansion, glomerular basement
membrane thickening, podocyte foot process fusion, and
TGF-1 expression (48). de Vriese’s group (49) examined
the effect of treatment with a monoclonal anti–VEGF-A
antibody in the early phase of diabetes induced by strep-
tozotocin. Administration of the antibody decreased hy-
perﬁltration, albuminuria, and glomerular hypertrophy in
diabetic rats. Although the effect on angiogenesis was not
speciﬁcally examined in this study, VEGF-A blockade
prevented the upregulation of eNOS associated with this
model (49). Other studies were performed in db/db mice
and the Zucker diabetic fatty rat (50,51). In db/db mice,
VEGF-A antibody treatment resulted in a reduction in
kidney weight, glomerular volume, basement membrane
thickness, and urinary albumin excretion (50); in the
Zucker diabetic fatty rat, VEGF-A antibody treatment
prevented glomerular hypertrophy. However, neither of
T
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abnormal angiogenesis. Similarly, Sung et al. (52) blocked
the phosphorylation of the VEGF-A receptors using the
pharmacological kinase inhibitor SU5416 in db/db mice
and found that this approach prevented the development
of albuminuria and glomerular basement membrane thick-
ening. Interestingly, blocking VEGF-A activation pre-
vented the loss of nephrin and improved structural
changes in podocyte foot processes in db/db mice. These
results suggest that VEGF-A could impair podocyte func-
tion, which may be an additional mechanism by which
VEGF-A causes urinary protein excretion. However, since
these studies did not examine the process of abnormal
angiogenesis per se, further experiments are required to
determine whether this beneﬁcial effect of anti–VEGF-A
therapy could be due to the blocking of VEGF-associated
angiogenesis.
Currently VEGF-A inhibitors are classiﬁed into four
groups (Table 2) and have been used in clinical practice.
Importantly, the efﬁcacy of these individual compounds is
not identical. For instance, the tyrosine kinase inhibitors
have greater anti-tumor efﬁcacy only at early stages of
cancer progression (53), whereas monoclonal antibodies
are capable of regressing tumor growth (54). In the kidney,
VEGF-A function is also complicated given that it has been
found to exhibit both deleterious and beneﬁcial effects
(rev. in 33). In fact, VEGF-A is found to be deleterious in
diabetic nephropathy but largely beneﬁcial in nondiabetic
animal models of renal disease. Hence, we need to be
cautious before using VEGF-A inhibitors in the diseased
kidney. Previously, the beneﬁcial effect of anti–VEGF-
antibodies was shown in two diabetic animal models:
streptozotocin-induced diabetic rats and db/db mice
(49,55). On the contrary, it has been postulated that a
potential adverse effect with VEGF-A inhibitors could be
endothelial injury because endothelial cells require
VEGF-A in physiological conditions. Eremina et al. (56)
demonstrated that bevacizumab, the anti–VEGF-antibody,
causes renal thrombotic microangiopathy partly due to
endothelial injury in patients. Similarly, Advani et al. (57)
demonstrated that VEGFR-2 tyrosine kinase inhibitors
exacerbated hypertension and renal disease in hyperten-
sive rats. Likewise, systemic overexpression of soluble
VEGFR-1 in normal animals was found to cause endothe-
liosis and podocyte injury, leading to proteinuria and
hypertension (58,59). In addition, the deleterious effect of
anti-VEGF antibodies could be attributed to the deposition
of VEGF–anti-VEGF complex, C3 deposition, and endothe-
lial swelling (54). However, in some experiments, it was
also shown that normal kidneys did not have any side
effects from VEGF inhibitors treatment (60,61).
Since endothelial cells require VEGF-A in physiological
conditions, substantial inhibition can cause endothelial
injury. In this regard, it may not be adequate to use
VEGF-A inhibitors in patients with normal kidney function
or in nondiabetic renal injury in which VEGF-A expression
is downregulated. In contrast, Gnudi and colleagues (48)
succeeded in treating diabetic nephropathy using podo-
cyte-speciﬁc overexpression of soluble VEGFR-1. In this
study, neither VEGF-A expression nor VEGFR-2 phosphor-
ylation was signiﬁcantly blocked by overexpression of
soluble VEGFR-1 in the diabetic kidney, suggesting that
VEGF-A function was partially inhibited. Thus, the “par-
tial” inhibition might be a means to treat diabetic nephrop-
athy without any adverse effects. Further clariﬁcation on
the adverse effects of VEGF-A inhibitors is required before
they may be used to treat diabetic patients.
Angiopoietins have been used therapeutically in several
diabetes situations. Administration of angiopoietin-1 has
been shown to suppress diabetic retinopathy by prevent-
ing leukocyte adhesion, endothelial cell injury, and blood-
retinal barrier breakdown (62). With regard to diabetic
nephropathy, Lee et al. (63) demonstrated that systemic
adenoviral delivery of COMP-Ang-1 (a modiﬁed form of
angiopoietin-1) reduced renal ﬁbrosis in db/db mice. How-
ever, this strategy also caused a signiﬁcant improvement
in hyperglycemia, an event possibly related to the systemic
administration of angiopoietin-1, which could itself, at
least partly, account for the amelioration of diabetic
nephropathy. Therefore, further experiments are required
to examine whether modulation of this pathway could be
a future treatment for patients with diabetic nephropathy.
Several studies have attempted to block angiogenesis
using other anti-angiogenic molecules in animal models, as
shown in Table 3 (13,14,16,64). Angiostatin is a potent
angiogenic inhibitor that blocks proliferation, induces
apoptosis, and prevents migration of endothelial cells in
vitro. In addition, angiostatin has anti-inﬂammatory ac-
tions by inhibiting leukocyte recruitment and both neutro-
phil and macrophage migration. In streptozotocin-induced
diabetic nephropathy, adenoviral-mediated delivery of an-
giostatin was found to alleviate albuminuria and glomeru-
lar hypertrophy (64). We also found a similar advantage of
angiostatin treatment in the remnant kidney model (65).
Similarly, endostatin, a potent inhibitor of angiogenesis
derived from type XVIII collagen (14), and tumstatin, an
angiogenic inhibitor derived from type IV collagen (16),
were both able to prevent glomerular hypertrophy, hyper-
ﬁltration, and albuminuria in type 1 diabetic mice. Inter-
estingly, these treatments were shown to prevent
mesangial expansion and inﬂammation and also to atten-
uate the increase in levels of VEGF-A and angiopoietin-2
normally observed in this model (14,16) independent of
blood pressure and blood glucose levels (Fig. 2). Similar
observations were made with 2-(8-hydroxy-6-methoxy-1-
oxo1H-2-benzopyran-3-yl) propionic acid (a small mole-
cule with anti-angiogenic activity) in db/db mice (13).
These novel treatments to prevent angiogenesis could be
considered for patients in early stages of diabetic
nephropathy.
What prospects are there for other novel therapies for
diabetic nephropathy? One area of interest may be in
examining the anti-angiogenic isoforms of VEGF-Axxxbi n
models of diabetic nephropathy, which may open new
avenues of treatment strategies. Another therapy could be
the use of RNA aptamers, which are oligonucleotidue
ligands that bind with high-afﬁnity to molecular targets.
TABLE 2
VEGF inhibitors
Function Drug name
Inhibition of VEGF secretion Iressa*
Tarceva*
Sequestration of VEGF Bevacizumab*
Ranibizumab*
Pegaptanib*
Blocking binding of VEGF to VEGFR DC101
Inhibitior of receptor tyrosine kinase Sunitinib*
Sorafenib*
*Approved by the U.S. Food and Drug Administration.
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1476 DIABETES, VOL. 58, JULY 2009One such aptamer that targets VEGF-A165 has been used
successfully in clinical trials to block ocular neovascular-
ization (66). Promising results have also been obtained
using small-molecule tyrosine kinase inhibitors to treat
type 1 diabetic mice (67); however, the kidneys were not
examined in these studies. Finally, other molecules in-
volved in angiogenic pathways such as the Notch family
(68) may provide interesting information in the pathobiol-
ogy and treatment of diabetic nephropathy. In this regard,
studies by Niranjan et al. (69) have already demonstrated
that lack of the Notch1 transcriptional partner Rbpj in
podocytes is able to modulate the progression of albumin-
uria in diabetic mice.
In conclusion, while the presence of abnormal angiogen-
esis was demonstrated more than a decade ago, we are
only beginning to unravel the pathophysiological impor-
tance of this event. Anti-angiogenic treatments can pre-
vent the progression of animal models of diabetic
nephropathy, but further studies are required before these
treatments can be used in a clinical setting. The fact that
diabetic nephropathy is currently still the leading cause of
end-stage renal disease points to the need for additional
treatment strategies. Thus, novel therapies that target
other angiogenic pathways such as the angiopoietin and
Notch families could be an attractive option to block
diabetic nephropathy in the future.
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